ABSTRACT
El receptor a soluble de la interleuquina 2 (sRaIL-2) ha sido considerado un marcador pronóstico en pacientes con linfoma No Hodgkin (LNH). El objetivo del trabajo consistió en determinar la significancia de los niveles del sRaIL-2 en pacientes con LNH, su correlación con factores clínico patológicos, biológicos y su valor pronóstico. Se procesaron muestras de suero de 43 nuevos casos de pacientes con LNH, pretratamiento, edades comprendidas entre 25-84 años, mediana 55 años, 33 (77%) LNH agresivos y 10 (23%) LNH indolentes. Según el Índice Pronóstico Internacional (IPI), 37 (86%) de bajo riesgo y 6 (14%) de alto riesgo, siendo el tiempo promedio de seguimiento de la enfermedad 30 meses (rango 3-48 meses). Se recolectaron 20 muestras de suero de controles sanos, donantes de banco de sangre, para determinar el valor de referencia. Las muestras de pacientes y controles se congelaron a -70ºC hasta su procesamiento. El sRaIL-2 se determinó por un inmunoensayo enzimático adsorbente (ELISA), sensibilidad 10 pg/ml y se consideraron elevados los niveles >2000 pg/ml. Los marcadores biológicos: Beta 2 microglobulina (B2M), Proteína C Reactiva (PCR), Velocidad de sedimentación globular (VSG), Albúmina sérica, Lactato deshidrogenasa (LDH), Aspartato amino transferasa (AST), Alanino amino transferasa (ALT) y Fosfatasa alcalina (ALP), se determinaron por métodos de inmunoensayo enzimático sobre micropartículas (MEIA), aglutinación directa, Wintrobe, colorimétrico y cinético, respectivamente. Los niveles séricos del sRaIL-2 en pacientes con LNH fueron significativamente superiores al del grupo control (p <0,001) y 26 (60%) de los pacientes expresaron niveles elevados del sRaIL-2 (p< 0,001). Se detectaron niveles del sRaIL-2 significativamente incrementados asociados a pacientes con estadio clínico (EC) III-IV (p= 0,02), síntomas B (p= 0,04), valores elevados de B2M (p= 0,01) y PCR (p= 0,05)...
Soluble Interleukin2 a receptor (sIL-2aR) has been considered as a prognostic marker in Non-Hodgkins lymphoma (NHL) patients. The aim of this study was to assess the significance of sIL-2aR levels in the pre-treatment serum of NHL patients, as well as its correlation with the clinical-pathological and biological factors and its prognostic value. Forthy-three serum samples from newly diagnosed NHL patients were processed before starting the treatment. The median age was 55 years old (range 25-84 years), 33 cases (77%) were classified as aggressive lymphomas and 10 cases (23%) as indolent lymphomas. According to the International Prognostic Index (IPI), 37 cases (87%) were classified as high risk group and 6 cases (14%) as low risk group. The average time of followups was 30 months (range 3-48 months). 20 healthy control samples from blood bank donors were collected for establishing the reference value. All patients and control samples were kept at -70ºC until processed. The sIL-2aR levels were determined by applying an enzyme-linked immunosorbent assay (ELISA), sensitivity 10 pg/ml. Values were considered elevated when they exceeded 2000 pg/ml. The biological markers: Beta 2 microglobulin (B2M), C-Reactive Protein (CRP), erythrocyte sedimentation rate (ESR), serum albumin, serum lactate dehydrogenase (LDH), aspartate amino transaminase (AST), alanine amino transaminase (ALT), alkaline phosphatase (ALP), were determined by the methods of microparticle enzyme immunoassay (MEIA), direct agglutination, Wintrobe, colorimetric and kinetic respectively. The sIL-2aR serum levels in the NHL patients were significantly higher than the control group (p< 0.001) and 26 (60%) of the patients expressed values higher than 2000 pg/ml (p<0.001). Significantly elevated serum levels of sIL-2aR were associated with clinical stage (CS) III-IV (p= 0.02), B symptoms (p= 0.04), elevated levels of B2M (p=0.01) and CRP (p=0.05)...